Busulfan Other names: Busulphan

Chemical formula: C₆H₁₄O₆S₂ Molecular mass: 246.302 g/mol PubChem compound: 2478

Therapeutic indications

Busulfan is indicated for:

Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation

Population group: only adults (18 years old or older)

Busulfan followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.

Busulfan following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.

Busulfan followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.2 mg/kg in 1-4 divided doses daily

4 mg/kg in 4 divided doses daily

Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Busulfan followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.

Busulfan following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.

Busulfan followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3.2-4.8 mg/kg in 4 divided doses daily

120-150 mg/m² in 4 divided doses daily

Essential thrombocythaemia

Population group: only adults (18 - 65 years old)

Essential thrombocythemia (clinical disorder)

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2-4 mg/kg in 2-4 divided doses daily

Myelofibrosis

Population group: only adults (18 - 65 years old)

Myelofibrosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2-4 mg/kg in 2-4 divided doses daily

Polycythemia vera

Population group: only adults (18 - 65 years old)

Vaquez's disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

4-6 mg/kg in 4 divided doses daily

Chronic myeloid leukaemia

Population group: only adults (18 - 65 years old)

Chronic myeloid leukemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.03-0.06 mg/kg once daily

Contraindications

Busulfan is contraindicated in the following cases:

Pregnancy

Pregnancy

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈